Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 olaparib in advanced homologous recombination-deficient cancers
2018-002966-37Phase 2Active
- Sponsor
- Belgian Society of Medical Oncology
- Start
- Mar 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of olaparib in cancer, sponsored by Belgian Society of Medical Oncology. Primary endpoint: Anti-tumor activity. Started Mar 2019; status: active.
02
Drugs
olaparib
03
Conditions
cancer
Beyond the preview
Go deeper on 2018-002966-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-002966-37.